At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RYZB RayzeBio, Inc.
Halted 02-23 16:00:00 EST
62.49
+0.00
0.00%
High62.49Low62.49Vol0.00
Open62.49D1 Closing62.49Amplitude0.00%
Mkt Cap3.74BTradable Cap2.18BTotal Shares59.92M
T/O17.33MT/O Rate0.00%Tradable Shares34.82M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity
seekingalpha  ·  05-23
Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity
Bristol-Myers Squibb Co :Q1 Eps $-5.89.Q1 Opdivo Revenue $2.08 Billion, Down 6%.
THOMSON REUTERS  ·  04-25
Bristol-Myers Squibb Co :Q1 Eps $-5.89.Q1 Opdivo Revenue $2.08 Billion, Down 6%.
BRIEF-Bristol Myers Posts Q1 Adj EPS $-4.40
Reuters  ·  04-25
BRIEF-Bristol Myers Posts Q1 Adj EPS $-4.40
Citigroup Inc. Invests $553000 in RayzeBio, Inc. (NASDAQ:RYZB)
Defense World  ·  03-23
Citigroup Inc. Invests $553000 in RayzeBio, Inc. (NASDAQ:RYZB)
AstraZeneca-Fusion deal reignites radiopharma space
seekingalpha  ·  03-19
AstraZeneca-Fusion deal reignites radiopharma space
IPO Roundup: Boundless Bio, NeOnc Technologies and more
seekingalpha  ·  03-12
IPO Roundup: Boundless Bio, NeOnc Technologies and more
Provectus Biopharmaceuticals (OTCMKTS:PVCT) versus RayzeBio (NASDAQ:RYZB) Head to Head Survey
Defense World  ·  03-10
Provectus Biopharmaceuticals (OTCMKTS:PVCT) versus RayzeBio (NASDAQ:RYZB) Head to Head Survey
Bristol-Myers Squibb: Turnaround Expected
seekingalpha  ·  03-08
Bristol-Myers Squibb: Turnaround Expected
Bristol Myers completes acquisition of RayzeBio - TipRanks.com
TipRanks  ·  02-27
Bristol Myers completes acquisition of RayzeBio - TipRanks.com
Bristol Myers Squibb Acquire RayzeBio for $4.1 Billion
European Pharmaceutical Manufacturer  ·  02-27
Bristol Myers Squibb Acquire RayzeBio for $4.1 Billion
Bristol Myers Squibb acquires RayzeBio for $4.1bn
Pharmaceutical Technology  ·  02-27
Bristol Myers Squibb acquires RayzeBio for $4.1bn
News On RayzeBio Inc. (RYZB) Now Under BMY
DowjonesLive  ·  02-27
News On RayzeBio Inc. (RYZB) Now Under BMY
RayzeBio, Inc. Completes Merger and Delists from Nasdaq
TIPRANKS  ·  02-26
RayzeBio, Inc. Completes Merger and Delists from Nasdaq
Bristol Myers Squibb completes RayzeBio acquisition By Investing.com
Investing.com Canada  ·  02-26
Bristol Myers Squibb completes RayzeBio acquisition By Investing.com
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
Business Wire  ·  02-26
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
Radiopharmaceutical market expected to reach ~$14B by 2032
seekingalpha  ·  02-26
Radiopharmaceutical market expected to reach ~$14B by 2032
Wall Street Breakfast: The Week Ahead
seekingalpha  ·  02-25
Wall Street Breakfast: The Week Ahead
Spotlight On Economic Data After Nvidia-Fueled Rally
seekingalpha  ·  02-24
Spotlight On Economic Data After Nvidia-Fueled Rally
Bristol Myers Squibb nears RayzeBio acquisition completion By Investing.com
Investing.com Canada  ·  02-23
Bristol Myers Squibb nears RayzeBio acquisition completion By Investing.com
Bristol Myers Wraps RayzeBio Tender Offer with 86% of Shares
Dow Jones  ·  02-23
Bristol Myers Wraps RayzeBio Tender Offer with 86% of Shares
No data available

Introduction

Company Name.
RayzeBio, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
Issue price:
--